Gene One Life Science

Gene One Life Science EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Gene One Life Science (011000.KS) as of Oct 26, 2026 is -46.80 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -39.39 B KRW — a change of 18.80% (lower).

EBITDA

-46.80 BKRW

YoY

18.80%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Gene One Life Science is 2025 -46.80 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Gene One Life Science was 2024 -39.39 B KRW. It decreases by 18.80% lower compared to the previous year.

The Gene One Life Science EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-9.34 B KRW
Jan 1, 2019
-6.72 B KRW
Jan 1, 2020
-16.74 B KRW
Jan 1, 2021
-24.70 B KRW
Jan 1, 2022
-35.43 B KRW
Jan 1, 2023
-69.25 B KRW
Jan 1, 2024
-39.39 B KRW
Jan 1, 2025
-46.80 B KRW
The Gene One Life Science EBITDA history
YEAREBITDAYoY
-46.80 BKRW+18.80%
-39.39 BKRW-43.12%
-69.25 BKRW+95.48%
-35.43 BKRW+43.41%
-24.70 BKRW+47.55%
-16.74 BKRW+149.14%
-6.72 BKRW-28.06%
-9.34 BKRW-61.34%
-24.16 BKRW+96.50%
-12.30 BKRW+363.90%
-2.65 BKRW-47.60%
-5.06 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Gene One Life Science Stock analysis

What does Gene One Life Science do? GeneOne Life Science, Inc. generates revenue through its biomedical contract manufacturing organization (CMO) services, producing DNA vaccines for disease prevention and treatment. The company also sells wicks under the brand INTERON for use in dress shirts, suits, and caps, and provides biopharmaceutical services including research, development, and manufacturing of plasmid DNA and DNA vaccines. Its leasing business involves nonresidential buildings. The primary buyers for the biomedical CMO services are likely pharmaceutical companies seeking contract manufacturing for DNA vaccines. INTERON wicks are purchased by apparel manufacturers producing dress shirts, suits, and caps. The leasing segment targets commercial property tenants requiring nonresidential space. The company serves the biomedical, textile, and real estate sectors through these distinct business segments. Gene One Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Gene One Life Science stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Gene One Life Science is -46.80 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Gene One Life Science changed from -39.39 B KRW to -46.80 B KRW, representing a 18.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Gene One Life Science since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Gene One Life Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Gene One Life Science

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Gene One Life Science